

1. McKenney JM, Jones PH, Adamczyk MA et al. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. *Curr Med Res Opin.* 2003;19(8):689-698.
2. Gómez- Briceño GA. Clinical experience in dyslipidemic patients treated either with rosuvastatin 10 mg/day or ezetimibe/simvastatin 10/20 mg/day in Mexico city. *Value in Health* 2007;10(3):A37.
3. Schuster H, Barter PJ, Stender S et al. Effects of switching statins on achievement of lipid goals: measuring effective reductions in cholesterol using rosuvastatin therapy (MERCURY I) study. *Am Heart J.* 2004 Apr;147(4):705-13.
4. Crestor (Rosuvastatina) IPP.
5. Vytorin (ezetimiba/simvastatina) IPP.
6. Jones PH, Davidson MH, Stein EA et al. Comparison of efficacy and safety of rosuvastatin versus atorvastatin, simvastatin and pravastatin across doses (STELLAR trial). *Am J Cardiol* 2003;92(2):152-60.
7. Fonseca FA, Ruiz A, Cardona-Muñoz EG et al. The DISCOVERY PENTA study: a Direct Statin Comparison of LDL-C Value--an Evaluation of Rosuvastatin therapy compared with atorvastatin. *Curr Med Res Opin.* 2005 Aug;21(8):1307-15.
8. Nissen SE, Nicholls SJ, Sipahi I et al. Effect of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis. The ASTEROID Trial. *JAMA.* 2006;295(13):1556-1565.
9. Nissen SE. Halting the progression of atherosclerosis with intensive lipid lowering: results from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial. *Am J Med.* 2005 Dec;118 Suppl 12A:22-7.
10. Crouse JR 3rd, Raichlen JS, Riley WA et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial *JAMA.* 2007 Mar 28;297(12):1344-53.
11. Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. *N Engl J Med* 2008.
12. Ridker PM, Macfadyen JG, Nordestgaard BG et al. Rosuvastatin for Primary Prevention Among Individuals With Elevated High-Sensitivity C-Reactive Protein and 5% to 10% and 10% to 20% 10-Year Risk *Circ Cardiovasc Qual Outcomes* 2010;3:447-452.
13. PLUTO: Pediatric Lipid-reduction Trial of rosuvastatin. Internet. Disponible en: <http://clinicaltrials.gov/ct2/show/NCT00355615> Consultado en septiembre de 2011.
14. Brewer HB. Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams. *Am J Cardiol.* 2003; 92(4B):23K-29K.